Literature DB >> 12673405

Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval.

Takashi Deguchi1, Mitsuru Yasuda, Shigeaki Yokoi, Ken-Ichiro Ishida, Masayasu Ito, Satoshi Ishihara, Ken Minamidate, Yoshimasa Harada, Kanhin Tei, Kentaro Kojima, Masayoshi Tamaki, Shin-Ichi Maeda.   

Abstract

The efficacy of antimicrobial regimens for the treatment of uncomplicated gonococcal urethritis depends partially upon the period of time (therapeutic time) during which the drug concentration in the blood after the concentration peak is greater than four times the minimum inhibitory concentration for 90% of clinical isolates of Neisseria gonorrhoeae (MIC(90)). A therapeutic time of at least 10 h is suggested as an important determinant for elimination of 95% or more of the infection. In this study, therapeutic times for a single 400-mg dose of cefixime at various MIC(90)s were calculated, and pharmacokinetic profiles of double-dosing of 200 mg cefixime at various intervals were simulated. Subsequently, a dosing interval of 6 h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval. For a single dose of 400 mg cefixime, therapeutic times were calculated to be 12.8, 9.1, 5.4, and 1.7 h for MIC(90)s of 0.06, 0.125, 0.25, and 0.5 microg/ml, respectively. In the simulation study of double-dosing of 200 mg cefixime at a 6-h interval, the therapeutic times for the MIC(90)s of < or =0.125 microg/ml were longer than 10 h. Of the 93 patients, 68 were evaluated for microbiological outcome, and N. gonorrhoeae was eradicated in 60 (88.2%). The MIC(90) of cefixime for the 61 isolates tested was 0.125 microg/ml. All strains with MICs of < or =0.06 microg/ml were eradicated, whereas 8 of 16 strains with MICs of > or =0.125 microg/ml persisted after treatment. This regimen would not be effective against infection by strains exhibiting cefixime MIC(90)s of > or =0.125 microg/ml. For such strains, a different regimen with a higher dose of cefixime would be required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673405     DOI: 10.1007/s10156-002-0204-8

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  44 in total

Review 1.  The use of cephalosporins for gonorrhea: an update on the rising problem of resistance.

Authors:  Juliet E Stoltey; Pennan M Barry
Journal:  Expert Opin Pharmacother       Date:  2012-05-30       Impact factor: 3.889

2.  Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae.

Authors:  Sho Takahata; Nami Senju; Yumi Osaki; Takuji Yoshida; Takashi Ida
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan.

Authors:  Masayasu Ito; Takashi Deguchi; Koh-Suke Mizutani; Mitsuru Yasuda; Shigeaki Yokoi; Shin-Ichi Ito; Yoshito Takahashi; Satoshi Ishihara; Yoshiaki Kawamura; Takayuki Ezaki
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 5.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

6.  Assessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae.

Authors:  Hsi Liu; Thomas H Taylor; Kevin Pettus; David Trees
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

7.  Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.

Authors:  Janice Y C Lo; K M Ho; Anna O C Leung; Felisa S T Tiu; Grand K L Tsang; Angus C T Lo; John W Tapsall
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

8.  Genome sequencing of a Neisseria gonorrhoeae isolate of a successful international clone with decreased susceptibility and resistance to extended-spectrum cephalosporins.

Authors:  David Hess; Abel Wu; Daniel Golparian; Sarah Esmaili; Will Pandori; Emilee Sena; Jeffrey D Klausner; Pennan Barry; Magnus Unemo; Mark Pandori
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 9.  Expedited partner therapy for sexually transmitted infections.

Authors:  Matthew Hogben; Sarah Kidd; Gale R Burstein
Journal:  Curr Opin Obstet Gynecol       Date:  2012-10       Impact factor: 1.927

10.  Threat to cefixime treatment for gonorrhea.

Authors:  Shigeaki Yokoi; Takashi Deguchi; Tomomi Ozawa; Mitsuru Yasuda; Shin-ichi Ito; Yasuaki Kubota; Masayoshi Tamaki; Shin-ichi Maeda
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.